IN2015DN03219A - - Google Patents

Info

Publication number
IN2015DN03219A
IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
Authority
IN
India
Prior art keywords
pridopidine
laquinimod
treating
neurodegenerative disorder
provides
Prior art date
Application number
Inventor
Michael Hayden
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2015DN03219A publication Critical patent/IN2015DN03219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a method of treating a patient afflicted with a neurodegenerative disorder , e.g., Huntington 's disease (HD), comprising administering to the patient laquinimod as an add- on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder , e.g. , HD. This invention also provides laquinimod for use as an add- on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder , e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
IN3219DEN2015 2012-09-27 2013-09-27 IN2015DN03219A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IN2015DN03219A true IN2015DN03219A (en) 2015-10-02

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3219DEN2015 IN2015DN03219A (en) 2012-09-27 2013-09-27

Country Status (13)

Country Link
US (7) US20150209346A1 (en)
EP (1) EP2900330A4 (en)
CN (1) CN104902958A (en)
AU (1) AU2013323131A1 (en)
BR (1) BR112015006623A2 (en)
CA (1) CA2884781A1 (en)
EA (1) EA201590655A8 (en)
HK (2) HK1211525A1 (en)
IL (1) IL237742A0 (en)
IN (1) IN2015DN03219A (en)
MX (1) MX2015003608A (en)
WO (1) WO2014052933A1 (en)
ZA (1) ZA201502600B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
RU2470013C2 (en) * 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-oxide and/or di-n-oxide derivatives of stabilisers/modulators of dopamine receptors, demonstrating improved profiles of cardio-vascular side effects
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2013034622A1 (en) 2011-09-07 2013-03-14 Neurosearch A/S Polymorphic form of pridopidine hydrochloride
MX347209B (en) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh The hydrobromide salt of pridopidine.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
KR20160110395A (en) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 Use of laquinimod to delay huntington's disease progression
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (en) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh PROCESS TO PREPARE PRIDOPIDINE
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
ES2938546T3 (en) * 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Treatment method of amyotrophic lateral sclerosis with pridopidine
CN113950328A (en) * 2019-06-12 2022-01-18 普瑞尼亚神经治疗有限公司 Compositions comprising pridopidine and analogs thereof for treating huntington's disease and symptoms thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765428A (en) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 The purposes of dopamine stabilizers
MX2011005096A (en) * 2008-11-13 2011-11-18 Link Medicine Corp Azaquinolinone derivatives and uses thereof.
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2820586A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
BR112015006623A2 (en) 2017-07-04
US20180250285A1 (en) 2018-09-06
WO2014052933A1 (en) 2014-04-03
US20150209346A1 (en) 2015-07-30
EA201590655A8 (en) 2016-07-29
EA201590655A1 (en) 2015-12-30
US20180133209A1 (en) 2018-05-17
CA2884781A1 (en) 2014-04-03
ZA201502600B (en) 2016-06-29
US20170319569A1 (en) 2017-11-09
HK1211525A1 (en) 2016-05-27
US20180369228A1 (en) 2018-12-27
HK1214553A1 (en) 2016-07-29
US20140088140A1 (en) 2014-03-27
AU2013323131A1 (en) 2015-05-07
CN104902958A (en) 2015-09-09
MX2015003608A (en) 2015-06-05
EP2900330A1 (en) 2015-08-05
IL237742A0 (en) 2015-05-31
EP2900330A4 (en) 2016-05-25
US20190117639A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IN2015DN03219A (en)
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015006234A (en) Use of akkermansia for treating metabolic disorders.
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
IN2015KN00414A (en)
MX2021005317A (en) Compositions and methods for transmucosal absorption.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112012022552A2 (en) use of fenoterol and fenoterol analogs in the treatment of gliobastomas and astrocytomas
MX2015012315A (en) Use of levocetirizine and montelukast in the treatment of traumatic injury.
MX2015000485A (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015010296A (en) Treatment of multiple sclerosis with laquinimod.
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
MX2016001177A (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine.
MX358512B (en) Methods of maintaining, treating or improving cognitive function.
MX370451B (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy.
IN2013MU01155A (en)
IN2013MU01252A (en)
IN2013MU01154A (en)
IN2013MU01249A (en)
IN2013MU01250A (en)